Navigation Links
Pharmaceutical companies provide EPA 100 drugs to help predict toxicity
Date:5/13/2010

WASHINGTON - The U.S. Environmental Protection Agency will continue validating its ToxCast screening tool by screening more than 100 drugs provided by Pfizer, GlaxoSmithKline, Sanofi-Aventis, and Merck. These drugs never entered the marketplace because they demonstrated different types and levels of toxicity when the pharmaceutical companies conducted the early stage clinical trials required by the Food and Drug Administration as part of the drug development process. EPA researchers will quickly screen the drugs and then compare those results with the clinical trial results. Assessment of the similarities and differences in the results will improve EPA's ability to screen chemicals for toxicity.

"For the first time, we'll have both ToxCast screening data and results from toxicology studies and human clinical trials," said Dr. Paul Anastas, EPA's assistant administrator of the Office of Research and Development. "This is an important step in accessing the treasure trove of data that the pharmaceutical industry has in ways that helps protect human health and the environment."

Because of the high cost and the long process of conducting chemical testing, only a small fraction of the thousands of available chemicals have been assessed for potential human health risk. EPA is using its ToxCast screening tool to help efficiently understand how chemicals may impact processes in the human body that could lead to adverse health effects. Currently, ToxCast includes 500 automated chemical screening tests that have assessed more than 300 environmental chemicals.

The clinical trial data will help EPA select the ToxCast screening tests and biological profiles that are the most predictive. The tests and profiles will be used as indicators of potential toxicity for future chemical screening. The ToxCast screening results will be available online for scientists and the interested public to use.

This collaboration was fostered by the International Life Sciences Health and Environmental Science Institute, a non-profit organization of international scientists representing academia, industry, regulatory agencies, and government institutions that come together to reach consensus on complex scientific questions. The organization adopted the inclusion of failed drug candidates into ToxCast as their emerging issue of 2009.


'/>"/>

Contact: Latisha Petteway
petteway.latisha@epa.gov
202-564-3191
U.S. Environmental Protection Agency
Source:Eurekalert

Related medicine news :

1. HIRC Research Alert: New Study Identifies Best Pharmaceutical Company Account Managers and Program Offerings
2. SDI Reports: Pharmaceutical Promotion Spending Indicates Trend Toward Electronic and Online Promotion
3. Impact Systems Successfully Completes EMC Documentum Migration for Global Pharmaceutical Client
4. Sponsoring by the pharmaceutical industry can bias the results of drug studies
5. Jazz Pharmaceuticals to Present at the Barclays Capital 2010 Global Healthcare Conference
6. Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2009 Results
7. Astellas Responds to OSI Pharmaceuticals Rejection
8. Top 10 Pharmaceutical Company Awards Comprehensive Cardiac Safety Study to iCardiac
9. Poniard Pharmaceuticals Reports Fourth Quarter and Year End 2009 Financial Results
10. Poniard Pharmaceuticals Presents Positive Survival Data from a Phase 2 Clinical Study of Picoplatin in Metastatic Prostate Cancer at the 2010 American Society of Clinical Oncology Genitourinary Cancers Symposium
11. Anthera Pharmaceuticals Completes Initial Public Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2017)... , ... May 23, 2017 , ... ... and Reconstructive Surgeon Dr. Kevin Sadati, is pleased to announce a new treatment ... collagen and elastin in their face, neck, and body through a virtually pain-free, ...
(Date:5/23/2017)... ... May 23, 2017 , ... Drs. Allen Huang and ... in Las Vegas, NV, and the importance of treating it immediately. They ... leading care for peri-implantitis, with or without a referral. As experienced periodontists and ...
(Date:5/23/2017)... ... May 23, 2017 , ... Diagnotes, an ... a standard feature on its secure clinical communication platform. The platform allows clinicians ... depending on the type and urgency of a situation. , “We know ...
(Date:5/23/2017)... , ... May 23, 2017 , ... Orbita’s Nathan Treloar ... May 23, 2017 in San Francisco. Titled Connected Health and IoT: Technology Innovators ... Event hosted by Parks Associates, a market research and consulting firm specializing in ...
(Date:5/23/2017)... , ... May 23, 2017 , ... ... receive treatment using the SPEED System™ Orthodontics, with or without a referral, from ... in El Segundo, CA, who is skilled in providing patients with the ...
Breaking Medicine News(10 mins):
(Date:5/4/2017)... 2017 Clarius Mobile Health, a digital ... scanners this week at the American Congress of ... San Diego, CA from ... the perfect tool for clinicians to easily confirm ... evaluate pregnancy-related complications like ectopic pregnancy and placenta ...
(Date:5/4/2017)... WAYNE, Pa. , May 4, 2017 /PRNewswire/ ... made from thermoplastics and other highly-engineered materials, is ... Microextrusion tubing has been developed in recent ... neurovascular interventional therapies and surgical applications. More expensive ... used to produce microextrusion tubing due to their ...
(Date:5/3/2017)...  Kalorama Information notes that transplant diagnostics is ... and this is projected to continue to 2021. ... or bone marrow transplants require histocompatibility between the ... this task. This according to a new report ... various PCR-based methodologies, Sanger sequencing and NGS used ...
Breaking Medicine Technology: